Signal
Merck and Kelun-Biotech advance sacituzumab tirumotecan for endometrial cancer after positive phase 3 results
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-05-18 15:28 UTCUpdated 2026-05-18 15:49 UTC
rss
clinical_trialsdrug_developmentfdaemabiotech_fundingr_and_d
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Merck and Kelun-Biotech have achieved positive phase 3 trial results for their TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) in certain endometrial cancer patients.
Entities
MerckKelun-Biotechsacituzumab tirumotecan
Score total
0.96
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- The phase 3 trial results were recently announced, marking a milestone in sac-TMT’s clinical development.
- Merck is actively pursuing regulatory clearance for a new indication based on this data.
- This trial is the first of many late-stage studies underway, highlighting accelerated development efforts.
Why it matters
- Positive phase 3 results support expanding sacituzumab tirumotecan’s approved uses beyond China.
- The trial is a key step in Merck’s global late-stage development strategy for this ADC.
- Success could contribute significantly to Merck’s long-term sales growth ambitions.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Merck and Kelun-Biotech have four approvals in China for sacituzumab tirumotecan.
- The phase 3 trial met primary endpoints in certain endometrial cancer patients.
- This trial is the first of 17 late-stage studies Merck is conducting globally for sac-TMT.
- Success in this trial supports Merck’s goal of $70 billion in annual sales by the next decade.
How sources frame it
- Fierce Pharma: neutral
- BioPharma Dive: neutral
Consolidated recent phase 3 trial news on sacituzumab tirumotecan with focus on clinical and regulatory progress.
All evidence
All evidence
Merck ADC, licensed from China, hits mark in first big global trial
BioPharma Dive · biopharmadive.com · 2026-05-18 15:49 UTC
Merck and Kelun-Biotech have already notched four approvals in China for their TROP2-directed ADC sacituzumab tirumotecan. Now, after meeting the primary endpoints in a phase 3 ...
Fierce Pharma (All) · fiercepharma.com · 2026-05-18 15:28 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercepharma.com (1)